Definium (DFTX) CEO Robert Barrow Sells 19,023 Shares, Receives Award

What Happened
Robert Barrow, CEO of Definium Therapeutics (DFTX), sold 19,023 common shares on Sept. 3, 2026 at a weighted average price of $37.94 for total proceeds of about $721,733. He also was reported as receiving (awarded) 40,000 common shares on Sept. 2, 2026 at $0.00 — these represent the first tranche of performance share units (PSUs) granted Feb. 3, 2026 and are contingent on meeting specified clinical and regulatory milestones.

Key Details

• Filing date: Sept. 4, 2026; reported transactions occurred Sept. 2 (award) and Sept. 3 (sale), filing shows no late-filing indication.
• Sale: 19,023 shares disposed, weighted average price $37.94, proceeds ≈ $721,733; sale prices ranged $37.46–$38.94 (multiple transactions).
• Award: 40,000 shares reported as an award (PSUs), $0 acquisition price; PSUs convert to shares only if milestones are met (first tranche).
• Tax/plan notes: The sale represents shares sold to satisfy withholding tax in connection with settlement of vested restricted performance units under a sell-to-cover election pursuant to a Rule 10b5-1 plan (adopted June 15, 2022).
• Other: Footnote notes 417 shares acquired under the company’s 2024 ESPP on Aug. 17, 2026 are included in amounts reported.
• Shares owned after transaction: not specified in the provided filing details.

Context
The 40,000-share entry is an award of performance-based units (contingent on milestones), not a cash purchase. The 19,023-share sale was executed under a pre-arranged 10b5-1 sell-to-cover arrangement to satisfy tax withholding tied to vesting—such sales are routine administrative actions and do not necessarily signal the insider’s market view.